olezarsen

Olezarsen is an antisense oligonucleotide designed to treat adults with familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood. It works by binding to and degrading apolipoprotein C-III (apoC-III) mRNA in hepatocytes, thereby decreasing apoC-III protein production. ApoC-III normally inhibits lipoprotein lipase and hepatic uptake of triglyceride-rich lipoproteins; thus, lowering apoC-III enhances the breakdown and clearance of plasma triglycerides and very low-density lipoproteins (VLDL). Olezarsen is administered as a subcutaneous injection once monthly. The drug was developed by Ionis Pharmaceuticals and is marketed under the brand name Tryngolza[1][2][5][6][7].

Brand names

Tryngolza

Other names

olezarsenISIS 678354 sodium saltISIS678354 sodium saltISIS-678354 sodium salt